Patients who had NAC-responsive tumors had a better recurrence free and overall survival compared to high-risk NMIBC patients (p<0.02 and p<0.02). Tumors ≥2cm were independently associated with cancer recurrence. About one-quarter of the patients the in NMIBC had a distance recurrence (p<0.01). There was no difference in recurrence location in patients between the three groups. In conclusion this study showed better survival in NAC responsive MIBC than in NMIBC.
This study further illustrate the importance of being able to identify response to chemotherapy and intravesical treatments to further improve patient survival from bladder cancer. In addition, this is a high-risk group where further characterization of disease biology would be a significant advance for bladder cancer.
Presented By: Aaron Brant, Medical Student, Johns Hopkins University, Baltimore, MD
Janet Baack Kukreja, MD, MPH, Urologic Oncology Fellow, Department of Urology, UT MD Anderson Cancer Center, Houston, TX
Ashish M. Kamat, MD, MBBS, FACS, Wayne B. Duddlesten Professor, Cancer Research, Department of Urology, UT MD Anderson Cancer Center, Houston TX
at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA